house · trading 2015-04-06 → 2019-05-02
*Notional-weighted price return on disclosed buys from the last ~3 years, marked to the latest close — open positions, per-share (share counts aren't disclosed, so this is price performance, not realized $ P&L).
▮ buys · ▮ sells
| Date | Ticker | Type | Amount | Est. price | Latest close | Return |
|---|---|---|---|---|---|---|
| 2019-05-02 | WAB | BUY | $1K–$15K | $74.98 | $260.86 2026-07-13 | +247.9% |
| 2019-04-26 | GSK | BUY | $1K–$15K | $40.40 | $52.29 2026-07-13 | +29.4% |
| 2016-09-06 | ABBV | SELL | $1K–$15K | $64.61 | $248.00 2026-07-13 | -283.8% exit |
| 2016-01-06 | ABBV | SELL | $1K–$15K | $57.38 | $248.00 2026-07-13 | -332.2% exit |
| 2015-04-06 | ABBV | SELL | $1K–$15K | $57.61 | $248.00 2026-07-13 | -330.5% exit |
Return: buys are marked to the latest close (open); sells tagged rt are realized round-trips vs a prior disclosed buy; exit = timing (how the stock moved after the sale, seller's perspective).
| Member | Shared tickers |
|---|---|
| Rohit Khanna | 3 · ABBV, GSK, WAB |
| James B. Renacci | 2 · ABBV, GSK |
| Thomas H Tuberville | 2 · ABBV, GSK |
| Thomas R Carper | 2 · ABBV, GSK |
| Virginia Foxx | 2 · ABBV, GSK |
| K. Michael Conaway | 2 · ABBV, GSK |
| John Boozman | 2 · ABBV, GSK |
| Kurt Schrader | 2 · ABBV, GSK |
| David P. Roe | 2 · ABBV, GSK |
| Kenny Marchant | 2 · ABBV, GSK |
| RICHARD M BURR | 2 · ABBV, GSK |
| Mike Kelly | 2 · ABBV, GSK |